NTRK1 and glioblastoma: While the vast majority of glioblastoma clinical research has focused on therapeutic targeting of receptor tyrosine kinase (RTK) signalling pathways, other avenues for targeted therapy include epigenetics, metabolism and immune-targeted therapies.